checkAd

     597  0 Kommentare Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO - Seite 2

    Learn more at https://www.mydecine.com.

    For more information, please contact:

    Media Contact:
    pr@mydecineinc.com

    Investor Relations:
    investorrelations@mydecineinc.com

    On behalf of the Board of Directors:

    Joshua Bartch, Chief Executive Officer

    contact@mydecineinc.com

    For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR+ at www.sedarplus.com or the Company’s website at www.mydecine.com.

    This news release contains forward-looking information about Canadian securities laws regarding the Company and its business. It relates to future events or performance and reflects management’s expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect,” “intends,” “anticipated,” “believes,” or variations (including negative variations) of such words and phrases or by stating that specific actions, events, or results “may,” "could," "would,” or “will” be taken, occur, or be achieved.

    Such forward-looking statements reflect management’s beliefs and are based on assumptions and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected, including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to protect and enforce its intellectual property adequately, the Company's ability to bring its products to commercial production, the continued growth of the global adaptive pathway medicine, natural health products, and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale, and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause effects not to be as anticipated, estimated, or intended. There can be no assurance that such information will be accurate, as actual results and future events could differ materially from those anticipated. These forward-looking statements are made as of the date hereof. The Company is not obligated to update or revise them to reflect new events or circumstances as required under applicable securities legislation.

    Seite 2 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from the NEO - Seite 2 VANCOUVER, British Columbia, Oct. 05, 2023 (GLOBE NEWSWIRE) - Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NF0) a biotechnology company engineering the next wave of innovative medications and treatment …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer